FDA.reportPublic FDA data

Abrysvo 60 MCG / 60 MCG per 0.5 ML Injection

RxCUI
2642148
RxNorm name
Abrysvo 60 MCG / 60 MCG per 0.5 ML Injection
Display name
Abrysvo 60 MCG / 60 MCG per 0.5 ML Injection
Full name
Abrysvo 60 MCG / 60 MCG per 0.5 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:19

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125769AbrysvoRespiratory Syncytial Virus Vaccine351(a)Rx2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
be18292e-b1a2-4815-a0ed-003efaa6bea3ABRYSVO 60 MCG / 60 MCG in 0.5 ML Injection [PSN] · 0.5 ML respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized 0.12 MG/ML / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized 0.12 MG/ML Injection [Abrysvo] [SBD] · Abrysvo 60 MCG / 60 MCG per 0.5 ML Injection [SY]314These highlights do not include all the information needed to use ABRYSVO safely and effectively. See full prescribing information for ABRYSVO. ABRYSVO ® (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use Initial U.S. Approval: 202320251223